Table 1.
The breast, patient and index cancer characteristics of the 348 women with 348 malignant lesions (index cancers), 317 of which showed enhancement with CEDM (TPs) and 13 of which were called “true false negative” (TFNs) included in our study group. The TFNs were the remaining cases of the group of false negatives, i.e. lesions with no perceptive contrast enhancement at the expected site of the index lesion, after excluding cases in which the cancer was outside the CEDM field of vision and those with abundant post biopsy hematoma at the site of the index lesion.
| Characteristic | Total sample (n = 348) | TP lesions (n = 317) | TFN lesions (n = 13) | |
|---|---|---|---|---|
| Breast density | BI-RADS A | 41 (11.8%) | 41 (12.9%) | – |
| BI-RADS B | 188 (54%) | 167 (52.7%) | 9 (69.2%) | |
| BI-RADS C | 81 (23.3%) | 74 (23.3%) | 3 (23.1%) | |
| BI-RADS D | 38 (10.9%) | 35 (11.1%) | 1 (7.7%) | |
| Index lesion on CI | Developing asymmetry | 3 (0.9%) | 3 (1.0%) | – |
| Architectural distortion | 9 (2.6%) | 9 (2.8%) | – | |
| Microcalcifications | 61 (17.5%) | 41 (12.9%) | 7 (53.8%) | |
| DM/DBT Mass | 2 (0.6%) | 2 (0.6%) | – | |
| US and DM/DBT Mass | 109 (31.3%) | 109 (34.4%) | 2 (15.4%) | |
| US Mass | 164 (47.1%) | 153 (48.3%) | 4 (30.8%) | |
| Palpable | Yes | 129 (37.1%) | 121 (38.2%) | 3 (23.1%) |
| No | 219 (62.9%) | 196 (61.8%) | 10 (76.9%) | |
| Personal History of BC | Yes | 45 (12.9%) | 36 (11.4%) | 3 (23.1%) |
| No | 303 (87.1%) | 281 (88.6%) | 10 (76.9%) | |
| BPE | Minimal | 137 (39.4%) | 126 (39.7%) | 5 (38.5%) |
| Mild | 133 (38.2%) | 121 (38.2%) | 5 (38.5%) | |
| Moderate | 59 (16.9%) | 53 (16.7%) | 3 (23.0%) | |
| Marked | 19 (5.5%) | 17 (5.4%) | – | |
| Biopsy | CNB | 281 (80.7%) | 270 (85.2%) | 5 (38.5%) |
| VAB | 67 (19.3%) | 47 (14.8%) | 8 (61.5%) | |
| Histology | DCIS | 35 (10.1%) | 21 (6.6%) | 8 (61.5%) |
| IDC | 186 (53.4%) | 174 (54.9%) | 4 (30.8%) | |
| ILC | 37 (10.6%) | 36 (11.4%) | – | |
| IDC/ILC | 26 (7.5%) | 25 (7.9%) | – | |
| Other invasive histotypes | 64 (18.4%) | 61 (19.2%) | 1 (7.7%) | |
| Dimensions at pathology | <10 mm | 110 (31.6) | 93 (29.3) | 9 (69.2%) |
| ≥10 mm | 238 (68.4%) | 224 (70.7%) | 4 (30.8%) | |
| Extension of the disease | Unifocal | 215 (61.8%) | 184 (58.0%) | 13 (100%) |
| Multifocal | 89 (25.6%) | 89 (28.1%) | – | |
| Multicentric | 44 (12.6%) | 44 (13.9%) | – | |
| Histological Grade | G1 | 81 (23.3%) | 74 (23.4%) | 3 (23.1%) |
| G2 | 170 (48.8%) | 150 (47.3%) | 9 (69.2%) | |
| G3 | 97 (27.9%) | 93 (29.3%) | 1 (7.7%) | |
| Estrogen Receptor Status | Positive | 281 (80.8%) | 265 (83.6%) | 4 (30.8%) |
| Negative | 32 (9.2%) | 31 (9.8%) | 1 (7.7%) | |
| Unknown | 35 (10.0%) | 21 (6.6%) | 8 (61.5%) | |
| Progesterone Receptor Status | Positive | 236 (67.8%) | 224 (70.7%) | 3 (23.1%) |
| Negative | 77 (22.2%) | 72 (22.7%) | 2 (15.4%) | |
| Unknown | 35 (10.0%) | 21 (6.6%) | 8 (61.5%) | |
| HER2 Receptor Status | Positive | 41 (11.8%) | 39 (12.3%) | 2 (15.4%) |
| Negative | 272 (78.2%) | 257 (81.1%) | 3 (23.1%) | |
| Unknown | 35 (10.0%) | 21 (6.6%) | 8 (61.5%) | |
| Ki67 | <20% | 134 (38.6%) | 82 (25.9%) | 3 (23.1%) |
| ≥20% | 179 (51.4%) | 214 (67.5%) | 2 (15.4%) | |
| Unknown | 35 (10.0%) | 21 (6.6%) | 8 (61.5%) | |
| Molecular Subtypes | Luminal A | 90 (25.9%) | 85 (26.8%) | 2 (15.4%) |
| Luminal B HER2- | 165 (47.4%) | 155 (48.9%) | 1 (7.7%) | |
| Luminal B HER2+ | 31 (8.9%) | 30 (9.5%) | 1 (7.7%) | |
| HER2 Enriched | 10 (2.9%) | 9 (2.8%) | 1 (7.7%) | |
| Triple Negative | 17 (4.9%) | 17 (5.4%) | – | |
| Not Classifiable | 35 (10.0%) | 21 (6.6%) | 8 (61.5%) | |
| Surgery | BCS | 246 (70.7%) | 215 (67.8%) | 13 (100%) |
| Mastectomy | 90 (25.9%) | 90 (28.4%) | – | |
| Bilateral BCS | 7 (2.0%) | 7 (2.2%) | – | |
| Bilateral Mastectomy | 5 (1.4%) | 5 (1.6%) | – |